Form 4: YK Bioventures Reduces Stake in Cero Therapeutics Holdings Through Series of Sales

YK Bioventures Opportunities Fund I, L.P. sold a significant portion of its Cero Therapeutics Holdings stock over three days, reducing its holdings from 17.6 million to 13 million shares.

Summary

• YK Bioventures Opportunities Fund I, L.P., through its general partner YK Bioventures Opportunities GP I, LLC, sold shares of Cero Therapeutics Holdings, Inc. common stock over three consecutive days.
• On December 11, 2024, 1,343,801 shares were sold at a price of $0.08 per share.
• On December 12, 2024, 1,614,541 shares were sold at a price of $0.07 per share.
• On December 13, 2024, 2,998,908 shares were sold at a price of $0.06 per share.
• Following these transactions, YK Bioventures Opportunities Fund I, L.P.'s holdings decreased from 17,618,618 to 13,005,169 shares.
• The sales were executed by YK Bioventures Opportunities Fund I, L.P., with YK Bioventures Opportunities GP I, LLC acting as the general partner.
• Mitchell W. Kossar and Gary K. Yeung, managing partners of YK Opps I GP, may be deemed to share voting and investment power over the shares held by YK Opps I.

Sentiment

Score: 3

Explanation: The document indicates a significant reduction in holdings by a major shareholder, which is generally a negative signal for the company's prospects. The decreasing sale prices also contribute to a negative sentiment.

Negatives

• YK Bioventures Opportunities Fund I, L.P. significantly reduced its stake in Cero Therapeutics Holdings, Inc., which could indicate a lack of confidence in the company's future prospects.

Risks

• The significant reduction in holdings by a major shareholder like YK Bioventures could negatively impact investor confidence and potentially lead to a decrease in the stock price.
• The decreasing sale prices over the three days may indicate a weakening market sentiment towards Cero Therapeutics Holdings, Inc.

Management Comments

• Mitchell W. Kossar and Gary K. Yeung, managing partners of YK Opps I GP, may be deemed to share voting and investment power over the shares held by YK Opps I.
• Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.

Industry Context

This filing indicates a significant change in ownership structure for Cero Therapeutics Holdings, which could be a reaction to the company's performance or broader market conditions in the biotechnology sector. It is common for investment funds to adjust their holdings based on their investment strategies and risk assessments.

Comparison to Industry Standards

• It is common for venture capital and private equity firms to adjust their holdings in portfolio companies, especially after a period of time or when certain milestones are reached.
• The scale of the sale by YK Bioventures is significant, suggesting a major shift in their investment strategy regarding Cero Therapeutics Holdings.
• Comparable transactions would include other instances of large shareholders reducing their stakes in publicly traded biotech companies, which are often driven by factors such as clinical trial results, regulatory approvals, or market conditions.

Stakeholder Impact

• The reduction in shareholding by YK Bioventures could negatively impact the share price, affecting current shareholders.
• The sales could also signal a potential shift in the company's strategic direction, which could impact employees and other stakeholders.

Key Dates

Keywords

Cero Therapeutics Holdings, YK Bioventures, stock sale, shareholding, insider trading, SEC Form 4